Brief: Summit Therapeutics Announces Proposed Public Offering Of Common Stock
09/06/2026 21:48
BRIEF-Summit Therapeutics Announces Proposed Public Offering Of Common Stock June 9 (Reuters) - Summit Therapeutics Inc SMMT.O:
SUMMIT THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
SUMMIT THERAPEUTICS - COMMENCES $500 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK
SUMMIT THERAPEUTICS - PROCEEDS TO FUND IVONESCIMAB RD, WORKING CAPITAL, AND GENERAL CORPORATE PURPOSES
Source text: ID:nBwbQbzkna
Further company coverage: SMMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Summit Therapeutics
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
Brief: Summit Therapeutics Announces Opening Of Global Phase Ii Study Of Ivonescimab-Based Regimens In Advanced Clear Cell Renal Cell Carcinoma
Factbox: Major drugmakers turn to China for licensing deals
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination (updated)